Ewing’s Sarcoma Treatment | Bone Cancer Care | I D Cancer Center
Rare Bone & Soft Tissue Cancer • Specialized Treatment • Better Outcomes with Early Care
I D Cancer Center, Sushant Golf City, Lucknow
I D Cancer Center, Sushant Golf City, Lucknow
Overview
Ewing’s Sarcoma is a rare but aggressive cancer that affects the bones and soft tissues, most commonly occurring in children, teenagers, and young adults. It often begins in the long bones of the legs, pelvis, ribs, or spine but can occur anywhere in the body.
Ewing’s sarcoma requires multidisciplinary, high-precision treatment involving chemotherapy, surgery, and/or radiation therapy. With modern care, survival rates have improved significantly.
At I D Cancer Center, we use advanced diagnostic facilities and evidence-based treatment protocols to ensure the best possible outcomes for young patients and their families.
Ewing’s Sarcoma is a rare but aggressive cancer that affects the bones and soft tissues, most commonly occurring in children, teenagers, and young adults. It often begins in the long bones of the legs, pelvis, ribs, or spine but can occur anywhere in the body.
Ewing’s sarcoma requires multidisciplinary, high-precision treatment involving chemotherapy, surgery, and/or radiation therapy. With modern care, survival rates have improved significantly.
At I D Cancer Center, we use advanced diagnostic facilities and evidence-based treatment protocols to ensure the best possible outcomes for young patients and their families.
Who Is Most Affected?
Ewing’s sarcoma mainly affects:
Children & teens (10–20 years)
Boys slightly more than girls
Rare in adults over 30
Ewing’s sarcoma mainly affects:
Children & teens (10–20 years)
Boys slightly more than girls
Rare in adults over 30
Causes & Risk Factors
The exact cause is unknown, but contributing factors include:
Genetic mutations (EWSR1-FLI1 fusion gene)
Rapid growth phases during adolescence
Family history (rare)
Not caused by injuries or infections
Ewing’s sarcoma is not hereditary and not contagious.
The exact cause is unknown, but contributing factors include:
Genetic mutations (EWSR1-FLI1 fusion gene)
Rapid growth phases during adolescence
Family history (rare)
Not caused by injuries or infections
Ewing’s sarcoma is not hereditary and not contagious.
Signs & Symptoms
Symptoms depend on tumor location but often include:
Symptoms depend on tumor location but often include:
Bone-Related Symptoms
Persistent bone pain
Swelling or a noticeable lump
Warmth or redness over the area
Pain worsening at night
Limited motion in the affected limb
Persistent bone pain
Swelling or a noticeable lump
Warmth or redness over the area
Pain worsening at night
Limited motion in the affected limb
General Symptoms
Fever
Fatigue
Unexplained weight loss
Fever
Fatigue
Unexplained weight loss
Advanced Symptoms
Bone fractures with minimal trauma
Difficulty walking or using a limb
Breathing issues (if chest wall is involved)
Any child or young adult with persistent bone pain must be evaluated early.
Bone fractures with minimal trauma
Difficulty walking or using a limb
Breathing issues (if chest wall is involved)
Any child or young adult with persistent bone pain must be evaluated early.
Diagnosis at I D Cancer Center
We follow optimized national & international guidelines for accuracy.
We follow optimized national & international guidelines for accuracy.
1. Clinical Evaluation
Complete physical examination
Detailed neurological and orthopedic assessment
Complete physical examination
Detailed neurological and orthopedic assessment
2. Imaging Tests
X-Ray (initial screening)
MRI – best for tumor extent & soft tissue involvement
CT Scan
PET-CT – detects spread and guides treatment
Bone Scan (if required)
X-Ray (initial screening)
MRI – best for tumor extent & soft tissue involvement
CT Scan
PET-CT – detects spread and guides treatment
Bone Scan (if required)
3. Biopsy (Essential for Diagnosis)
Image-guided core needle biopsy
Histopathology + Immunohistochemistry (CD99 positive)
Molecular testing for EWSR1 gene fusion
Image-guided core needle biopsy
Histopathology + Immunohistochemistry (CD99 positive)
Molecular testing for EWSR1 gene fusion
4. Staging
Checks for spread to:
Lungs
Bone marrow
Other bones
Checks for spread to:
Lungs
Bone marrow
Other bones
Treatment Options
Ewing’s Sarcoma requires a multimodality approach, and outcomes improve with coordinated treatment.
Ewing’s Sarcoma requires a multimodality approach, and outcomes improve with coordinated treatment.
⭐ 1. Chemotherapy (First Step)
Most patients receive systemic chemotherapy to:
Shrink the tumor
Kill microscopic spread
Improve surgical outcomes
Common regimens include:
VDC/IE (Vincristine + Doxorubicin + Cyclophosphamide / Ifosfamide + Etoposide)
Most patients receive systemic chemotherapy to:
Shrink the tumor
Kill microscopic spread
Improve surgical outcomes
Common regimens include:
VDC/IE (Vincristine + Doxorubicin + Cyclophosphamide / Ifosfamide + Etoposide)
⭐ 2. Surgery
Performed at specialized orthopedic oncology centers.
Options include:
Limb-sparing surgery
Tumor resection
Reconstruction with prosthesis or bone graft
Rarely, amputation (only when necessary)
Postoperative therapy continues at I D Cancer Center.
Performed at specialized orthopedic oncology centers.
Options include:
Limb-sparing surgery
Tumor resection
Reconstruction with prosthesis or bone graft
Rarely, amputation (only when necessary)
Postoperative therapy continues at I D Cancer Center.
⭐ 3. Radiation Therapy
Used when:
Surgery is not possible
Tumor margins are not clear
For local control in high-risk disease
At I D Cancer Center, we offer precision radiotherapy using:
IMRT
IGRT
VMAT
SRS/SBRT (for metastasis or specific bone sites)
Benefits:
High control rates
Reduced damage to surrounding healthy tissues
Better functional outcomes
Used when:
Surgery is not possible
Tumor margins are not clear
For local control in high-risk disease
At I D Cancer Center, we offer precision radiotherapy using:
IMRT
IGRT
VMAT
SRS/SBRT (for metastasis or specific bone sites)
Benefits:
High control rates
Reduced damage to surrounding healthy tissues
Better functional outcomes
⭐ 4. Targeted & Emerging Therapies
Used in recurrent/metastatic cases:
IGF-1R inhibitors
PARP inhibitors
Immunotherapy (in select cases)
Used in recurrent/metastatic cases:
IGF-1R inhibitors
PARP inhibitors
Immunotherapy (in select cases)
Survivorship & Long-Term Care
We provide continuous care throughout recovery:
Physiotherapy & rehabilitation
Psychological counselling
Nutritional support
Regular MRI/PET follow-up
Monitoring for late effects of treatment
Most young patients return to school, sports, and normal life with good long-term results.
We provide continuous care throughout recovery:
Physiotherapy & rehabilitation
Psychological counselling
Nutritional support
Regular MRI/PET follow-up
Monitoring for late effects of treatment
Most young patients return to school, sports, and normal life with good long-term results.
Prognosis
Survival depends on the stage and response to therapy:
Localized disease: 70–80% survival
Metastatic disease: 40–50% with modern treatment
Early detection improves outcomes significantly
Survival depends on the stage and response to therapy:
Localized disease: 70–80% survival
Metastatic disease: 40–50% with modern treatment
Early detection improves outcomes significantly
